Amgen: We Expect To Double Biosimilar Sales By 2030

Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue

 
• By Dean Rudge
  
AMGEN_1174421407_1200.jpg
Amgen is the market leader in Europe for biosimilar adalimumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products